From July 27th to 29th, 2023, Anling Biomed (Shenzhen) Co., Ltd. (hereinafter referred to as "Anling Shenzhen"), a wholly owned subsidiary of ZSHK Laboratories Limited. (hereinafter referred to as "ZSHK"), was invited to participate in the 2023 Shenzhen International Biomedical Industry Innovation and Development Conference. They had a booth at the venue (booth number: A11) and welcomed visitors from all walks of life for exchanges.

The theme of this conference was "Cross-border Integration, Deep into the Future". It included a closed-door meeting for medical leaders, a main forum, and nine professional theme forums. The conference focused on in-depth discussions on topics such as the latest national policies in the medical and health industry, cutting-edge technologies and investments, the integration of IT and BT, achievements transformation and industry-academia-research collaboration, as well as overseas expansion and internationalization. With the pioneering spirit of Shenzhen, the conference aimed to promote cross-border integration and push the industry towards breakthrough development. COO Jin Yi from ZSHK, who is also the General Manager of Anling (Shenzhen), will deliver a keynote speech on "Design and Focus of Non-clinical Research in New Drug Development" at the "Forum Four: Pharmaceutical Innovation Forum".

Scan the code to view the latest complete conference schedule.